We are focused on developing next generation small molecules which modify the activity of the JAK kinase family and have best-in-class potential. Our lead development candidate, SDC 1801, simultaneously inhibits TYK2 and JAK1. SDC1801 is a potential treatment for a range of autoimmune diseases. We plan (subject to regulatory approval) to commence clinical development as soon as we can obtain regulatory approval, with an initial focus on psoriasis.
Sareum is also developing SDC1802, a TYK2/JAK1 inhibitor with a potential application for cancer immunotherapy.
Additionally, Sareum has an economic interest in SRA737, a clinical-stage, oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms. SRA737 has completed two Phase 2 clinical trials, conducted by former licence partner, Sierra Oncology.